 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C24H22FNO |
| Molar mass | 359.444 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole) is arecreationaldesigner drug that acts as a potent but nonselectivefull agonist for thecannabinoid receptor.[3] It is part of theAM series of cannabinoids discovered byAlexandros Makriyannis atNortheastern University.
Convulsions have been reported[4] including at doses as low as 10 mg.[5]
AM-2201 is afull agonist forcannabinoid receptors. Affinities are: with aKi of 1.0 nM atCB1 and 2.6 nM atCB2.[6] The 4-methylfunctional analogMAM-2201 probably has similar affinities.[original research?] AM-2201 has an EC50 of 38 nM for human CB1 receptors, and 58 nM for human CB2 receptors.[7] AM-2201 producesbradycardia and hypothermia in rats at doses of 0.3–3 mg/kg, comparable to the potency ofJWH-018 in rats, suggesting potent cannabinoid-like activity.[7]
AM-2201metabolism differs only slightly from that ofJWH-018. AM-2201N-dealkylation produces fluoropentane instead ofpentane (or plainalkanes in general).[citation needed]
A forensic standard of AM-2201 is available, and the compound has been posted on the Forendex website of potential drugs of abuse.[8]
In the United States, AM-2201 is aSchedule I controlled substance.[9]
